Zuo W, Wang Z, Qian J, Ma X, et al. QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controll Br J Cancer 2024 Jun 21. doi: 10.1038/s41416-024-02751.
PMID: 38906970